Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
LA JOLLA, Calif., Sept. 8, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the presentation of recent advances in its microRNA therapeutic preclinical programs for the treatment of metabolic diseases and cancer. Specifically, Neil W. Gibson, Ph.D., Regulus' chief scientific officer will provide updates on the company's programs targeting microRNA-33 and microRNA-21 at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society held Sept. 8–10, 2011, in Copenhagen, Denmark. In a talk titled "Therapeutic Targeting of microRNAs," Dr. Gibson will present new data demonstrating that the inhibition of microRNA-33 with proprietary oligonucleotide anti-miRs in animal models increased levels of HDL-cholesterol (the 'good' cholesterol) and reduced levels of triglycerides. Additional preclinical data presented by Regulus confirmed that microRNA-21 is upregulated in human cancers and that microRNA-21 inhibition impacts tumor burden and significantly increases survival in preclinical models of hepatocellular carcinoma.
"Our exciting data show that inhibiting dysregulated microRNAs with our proprietary anti-miR oligonucleotides are effective at altering disease pathogenesis in animal models and provide us confidence to move these programs forward into clinical development," said Dr. Gibson. "Indeed, anti-miRs targeting miR-33 show promise as a novel strategy for treatment of cardiovascular disease and metabolic syndrome while anti-miRs targeting miR-21 demonstrate robust efficacy in pre-clinical tumor models."
Data updates will be made on the following programs:
miR-33. Regulus is developing microRNA therapeutics targeting miR-33 using proprietary chemically modified anti-miR oligonucleotides delivered systemically. microRNA-33a and b (miR-33a/b), whi